About Lonza
Lonza is a Healthcare company based in Basel (Switzerland) founded in 1999, and was acquired by Lonza in November 2009. Immunogenicity services are offered for structure-based protein and peptide design. It operates on a Professional Services and Managed Services model. Lonza offers products and services including In Silico & In Vitro Services, Antibody Humanization and Deimmunization, and Protein Engineering. Its focus areas include Biotechnology and Biopharmaceuticals.
Company details
Lonza is involved in offering comprehensive in silico and in vitro services for early drug development, focusing on biotherapeutics. Services such as manufacturability assessment, immunogenicity testing, antibody humanization, and protein engineering are provided to de-risk and optimize drug candidates. The company supports the biopharmaceutical sector with solutions for mammalian and microbial applications, including non-GMP and GMP protein production. Additionally, specialized offerings in bioconjugates, ADCs, and parenteral drug products are developed to address challenges in therapeutic protein safety and vaccine efficacy. Operations span multiple global locations to serve a wide range of clients in the healthcare industry.
Products & Services of Lonza
Lonza offers a comprehensive portfolio of products and services, including In Silico & In Vitro Services, Antibody Humanization and Deimmunization, and Protein Engineering.
Services for manufacturability and immunogenicity are provided comprehensively.
Antibody humanization services are offered to reduce immunogenicity risks.
Protein engineering solutions are provided to optimize therapeutic proteins.
Apps and channels of Lonza
its YouTube channel Lonza has 4.15K subscribers and 30 videos.
Videos from Lonza
The most watched videos on Lonza's YouTube channel, Lonza (4.15K subscribers). Click a video to play it here.
More on Lonza.
Funding Insights of Lonza
- Total Rounds 2
- Last Round Unspecified — $100,000
- First Round $670,685
(Jun 2007)
- Investors Count 4
All 2 funding rounds of Lonza with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $100,000 | Unspecified | – | – | |
| Jun 2007 | $670,685 | Unspecified | – | – |
5 investors in total: 5 institutional.
Investors in Lonza
Lonza has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Lonza, Upekkha and VIB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AI startup acceleration and networking services are offered globally. | 2017 | upekkha.io | Bengaluru, India | |
| baekelandfonds.be | ||||
Full-service corporate advisory is provided to businesses in India. | trustgroup.in | Mumbai, India | ||
VIB is recognized as a leading biotechnology research institute. | 1995 | vib.be | Ghent, Belgium | |
CDMO services for pharma, biotech, and specialty ingredients are provided. | 1897 | lonza.com | Basel, Switzerland |
Investor details for Lonza
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lonza
4 dated milestones of Lonza across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Lonza is founded.
- Funding First funding round of $671K.
- Exit Acquired by Lonza.
- Funding Latest funding round, Unspecified, of $100K.
Web traffic of Lonza
Websites that share an audience with Lonza (algonomics.com).
Websites whose visitors overlap most with Lonza. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genego.com | 100% | View details | |||
biobind.com | biobind.com | 100% | – | ||
| bioxing.com | 100% | View details | |||
| ingenuity.com | 100% | 24.3K | #619,156 | View details | |
| io-informatics.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for Lonza
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Lonza
Lonza was founded in 1999 and raised its 1st funding round 8 years after it was founded.
Lonza is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Lonza is involved in offering comprehensive in silico and in vitro services for early drug development, focusing on biotherapeutics. Services such as manufacturability assessment, immunogenicity testing, antibody humanization, and protein engineering are provided to de-risk and optimize drug candidates. The company supports the biopharmaceutical sector with solutions for mammalian and microbial applications, including non-GMP and GMP protein production. Additionally, specialized offerings in bioconjugates, ADCs, and parenteral drug products are developed to address challenges in therapeutic protein safety and vaccine efficacy. Operations span multiple global locations to serve a wide range of clients in the healthcare industry.
Lonza offers In Silico & In Vitro Services, Antibody Humanization and Deimmunization, and Protein Engineering.
Lonza operates through Lonza.
Yes. Lonza was acquired by Lonza in November 2009.